December 6, 2018

To	To
Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sirs,

Sub: Clarification on news item appeared on Business Standard dated December 06, 2018 captioned "Aurobindo faces US suit over impurities"

Ref : BSE Letter No. L/SURV/ONL/RV/ZS/ (2018-2019)/ 148 dated December 6, 2018
NSE Letter No.NSE/CM/Surveillance/7716 dated December 06, 2018

This has reference to your above cited letters seeking clarification on the subject matter.

In this regard, we inform you that we have not yet been served with the legal notice as to the institution of legal proceedings against the Company as alleged in the article but we learnt about the alleged proceedings from the media.

We further inform you that as and when we receive the notice about the institution of proceedings against the Company, we take legal advice and communicate suitably at an appropriate time.

Please take the information on record.

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED

B. Re.

B.Adi Reddy
Company Secretary

AUROBINDO PHARMA LTD. HYDERABAD, INDIA.